Source: Annual Congress 2002 - Interstitial lung disease
Disease area: Interstitial lung diseases

Abstract

INTRODUCTION:Interferon –gamma 1b, has been reported to be of benefit in the treatment of IPF. Colhicine is suggested as first line therapy for patients' refractory to corticosteroids.
AIM: To compare IFN-γ; (200μg SC, 3/wk) and colchicine (1mg/day, PO) plus 10 mg prednisone in a multicenter, randomized, parallel study.
METHODS: Until February 2002, 27 patients (age range, 49-82 yr; 24 male) entered the study after a two-month run in period with prednisone. Ten patients (37%) are treated with colchicine and 17 (63%) with IFN-γ;, following a randomized allocation. All patients fulfilled the established criteria for the diagnosis of IPF and 19 (70.4%) had histologically proven disease. Clinical data, PFTs, arterial blood gases and imaging (HRCT, DTPA, CXR) were recorded at baseline and at follow up.
RESULTS: In a median follow up of 11 months, two patients died from the colchicine group at 3 and 9 months of treatment. One patient withdrew from the study due to IFN-γ; tolerance. After six months of treatment, 50% of patients improved, 40% remained stable and 10% deteriorated in the IFN-γ; group, while 60% remained stable and 40% deteriorated in the Colhicine group, according to the ATS criteria. Patients of the IFN-γ; group tended to have improvement of dyspnea after 6 months of treatment (p=0.07).
CONCLUSION: These preliminary data show that IFN-γ; is well tolerated and could be a promising treatment for IPF.

Rating:

Share or cite this content

Citations should be made in the following way:
K. M. Antoniou, M. A. Dimadi, C. Mermigis, R. Trigidou, C. Labrakis, A. Rapti, P. Latsi, J. Drositis, N. Bachlitzanakis, A. G. Nicholson, V. Polychronopoulos, D. Bouros (Iraklion, Athens, Iraklio, Greece; London, United Kingdom). Comparison of Interferon gamma-1b (IFN-γ)and colcicine in the treatment of Idiopathic pulmonary fibrosis: preliminary results of a prospective, multicenter randomised study. Eur Respir J 2002; 20: Suppl. 38, 3754

Member's Comments

No comment yet.

Related content which might interest you: Preliminary results of a prospective, multicentric randomized study comparing Interferon Gamma-1b (IFN-γ) and colchicine in the treatment of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2003 - Interstitial lung diseases Year: 2003 A randomized, double-blind, placebo-controlled, phase III study of the safety and efficacy of interferon gamma-1b in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2007 - Clinical trial: new biological approaches to respiratory diseases Year: 2007 Concomitant corticosteroid with anti-fibrotic therapy for idiopathic pulmonary fibrosis: a prospective multicenter study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Nutritional assessment in idiopathic pulmonary fibrosis: a prospective multicentre study Source: ERJ Open Res, 8 (1) 00443-2021; 10.1183/23120541.00443-2021 Year: 2022 Azithromycin for the treatment of cough in idiopathic pulmonary fibrosis: A randomized controlled cross-over pilot trial. Source: Virtual Congress 2020 – Chronic cough: only symptom or disease? Year: 2020 Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study Source: ERJ Open Res, 6 (1) 00172-2019; 10.1183/23120541.00172-2019 Year: 2020 RCT Abstract - Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomized, double-blind, placebo-controlled, phase 3 trial Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs Year: 2021 Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial Source: Eur Respir J 2013; 42: 1622-1632 Year: 2013 Recent clinical trials in idiopathic pulmonary fibrosis and the BUILD-1 study Source: Eur Respir Rev 2008; 17: 116-122 Year: 2008 Real-life data on the safety and tolerability of Pirfenidone versus Nintedanib in Idiopathic Pulmonary Fibrosis (IPF) patients: A single-centre retrospective study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis Source: Eur Respir J, 53 (3) 1801992; 10.1183/13993003.01992-2018 Year: 2019 A feasibility, randomised controlled trial of a complex breathlessness intervention in idiopathic pulmonary fibrosis (BREEZE-IPF): study protocol Source: ERJ Open Res, 5 (4) 00186-2019; 10.1183/23120541.00186-2019 Year: 2019 Late Breaking Abstract - Efficacy and safety of eliapixant in refractory chronic cough: Results of the PAGANINI 12-week, randomized, placebo-controlled Phase 2b study Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021 Bosentan does not improve outcome in patients with steroid-resistant pulmonary sarcoidosis – Results from a double-blind placebo-controlled phase 2 trial Source: International Congress 2014 – Sarcoidosis Year: 2014 Efficacy of combined therapy with pirfenidone and inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomized controlled phase 3 trial Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments Year: 2018 Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study Source: ERJ Open Res, 4 (4) 00084-2018; 10.1183/23120541.00084-2018 Year: 2018 A multicentre, observational cohort study to determine the efficacy and safety of lumacaftor/ivacaftor in patients with severe lung disease and cystic fibrosis Source: International Congress 2019 – Advances in care and monitoring of cystic fibrosis Year: 2019 Maintenance after pulmonary rehabilitation in COPD: a randomised trial. Preliminary results Source: Eur Respir J 2004; 24: Suppl. 48, 245s Year: 2004 A Phase 2, double-blind, placebo-controlled study of N–acetylcysteine in combination with pirfenidone in patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 6 Year: 2014 Preliminary results of pulmonary rehabilitation in interstitial lung diseases: A randomised controlled trial B32220095560 Source: Annual Congress 2011 - Exercise training: new populations, new techniques Year: 2011